フォルキシガ市場：市場規模、予測、新たな洞察-2032年

フォルキシガ（米国外製品名：FORXIGA）（一般名：ダパグリフロジン）は、ファースト・イン・クラスの経口1日1回投与SGLT2阻害薬です。調査は、心臓、腎臓、膵臓の間の基本的な関連性を考慮すると重要な知見である臓器を保護しながら、心腎疾患の予防と遅延におけるフォルキシガの有効性を示しています。

フォルキシガは、10歳以上の成人および小児において、食事療法と運動療法の補助として、コントロール不十分な2型糖尿病の治療薬として承認されています。また、DAPA-HFおよびDAPA-CKD第III相試験の結果に基づき、HFrEFおよびCKD治療薬としても承認されています。

フォルキシガは現在、急性心筋梗塞または心臓発作後の2型糖尿病のない患者を対象とした、レジストリをベースとした初の無作為化比較試験であるDAPA-MI第III相試験で試験中です。DAPA-MI試験はUppsala Clinical Research Center（UCR）および英国のMyocardial Ischaemia National Audit Project（MINAP）と共同で実施されています。

同社の2022年第3四半期報告書によれば、第III相（DAPA-MI）試験のデータ読み出しは2023年下半期までに行われる予定です。主要な承認申請は2023年以降と推定されます。

今後数年間で、心筋梗塞の市場シナリオは、世界中の広範な調査と医療費の増加により変化することが予想されます。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、FARXIGAの優位性に影響を与える可能性のある機会を模索しています。他の心筋梗塞治療薬もフォルキシガと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国における心筋梗塞治療薬のフォルキシガ市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 心筋梗塞におけるフォルキシガの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 フォルキシガ市場評価

• 心筋梗塞におけるフォルキシガ市場の見通し
• 主要7ヶ国分析
  • 主要7ヶ国における心筋梗塞治療薬フォルキシガの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: FARXIGA, Clinical Trial Description, 2023
• Table 2: FARXIGA, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: FARXIGA Market Size in the 7MM, in USD million (2019-2032)
• Table 6: FARXIGA Market Size in the US, in USD million (2019-2032)
• Table 7: FARXIGA Market Size in Germany, in USD million (2019-2032)
• Table 8: FARXIGA Market Size in France, in USD million (2019-2032)
• Table 9: FARXIGA Market Size in Italy, in USD million (2019-2032)
• Table 10: FARXIGA Market Size in Spain, in USD million (2019-2032)
• Table 11: FARXIGA Market Size in the UK, in USD million (2019-2032)
• Table 12: FARXIGA Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: FARXIGA Market Size in the 7MM, USD million (2019-2032)
• Figure 2: FARXIGA Market Size in the United States, USD million (2019-2032)
• Figure 3: FARXIGA Market Size in Germany, USD million (2019-2032)
• Figure 4: FARXIGA Market Size in France, USD million (2019-2032)
• Figure 5: FARXIGA Market Size in Italy, USD million (2019-2032)
• Figure 6: FARXIGA Market Size in Spain, USD million (2019-2032)
• Figure 7: FARXIGA Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: FARXIGA Market Size in Japan, USD million (2019-2032)

"FARXIGA Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about FARXIGA for myocardial infarction in the seven major markets. A detailed picture of the FARXIGA for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the FARXIGA for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FARXIGA market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Drug Summary:

FARXIGA (known as FORXIGA outside the US) (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor. Research has shown FARXIGA's efficacy in preventing and delaying cardiorenal disease while protecting the organs - important findings given the underlying links between the heart, kidneys, and pancreas.

FARXIGA is approved in adults and children aged 10 and above for treating insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. FARXIGA is also approved for HFrEF and CKD treatment based on the findings of the DAPA-HF and DAPA-CKD Phase III trials.

FARXIGA is currently being tested in the DAPA-MI Phase III trial, a first-of-its-kind, registry-based randomized controlled trial in patients without type 2 diabetes following an acute MI or heart attack. The DAPA-MI trial is conducted in collaboration with Uppsala Clinical Research Center (UCR) and Myocardial Ischaemia National Audit Project (MINAP) in the UK.

As per the company's Q3 2022 report, data readouts from the Phase III (DAPA-MI) trial are anticipated by 2H 2023. With an estimated key regulatory submission acceptance after 2023.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the FARXIGA description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
• Elaborated details on FARXIGA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the FARXIGA research and development activities in myocardial infarction across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around FARXIGA.
• The report contains forecasted sales of FARXIGA for myocardial infarction till 2032.
• Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
• The report also features the SWOT analysis with analyst views for FARXIGA in myocardial infarction.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FARXIGA Analytical Perspective by DelveInsight

• In-depth FARXIGA Market Assessment

This report provides a detailed market assessment of FARXIGA for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• FARXIGA Clinical Assessment

The report provides the clinical trials information of FARXIGA for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FARXIGA dominance.
• Other emerging products for myocardial infarction are expected to give tough market competition to FARXIGA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FARXIGA in myocardial infarction.
• Our in-depth analysis of the forecasted sales data of FARXIGA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FARXIGA in myocardial infarction.

Key Questions:

• What is the product type, route of administration and mechanism of action of FARXIGA?
• What is the clinical trial status of the study related to FARXIGA in myocardial infarction and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FARXIGA development?
• What are the key designations that have been granted to FARXIGA for myocardial infarction?
• What is the forecasted market scenario of FARXIGA for myocardial infarction?
• What are the forecasted sales of FARXIGA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to FARXIGA for myocardial infarction?
• Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?

Table of Contents

1. Report Introduction

2. FARXIGA Overview in myocardial infarction

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. FARXIGA Market Assessment

• 5.1. Market Outlook of FARXIGA in myocardial infarction
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of FARXIGA in the 7MM for myocardial infarction
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of FARXIGA in the United States for myocardial infarction
  • 5.3.2. Market Size of FARXIGA in Germany for myocardial infarction
  • 5.3.3. Market Size of FARXIGA in France for myocardial infarction
  • 5.3.4. Market Size of FARXIGA in Italy for myocardial infarction
  • 5.3.5. Market Size of FARXIGA in Spain for myocardial infarction
  • 5.3.6. Market Size of FARXIGA in the United Kingdom for myocardial infarction
  • 5.3.7. Market Size of FARXIGA in Japan for myocardial infarction

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options